IMP3 Expression as a Potential Tumour Marker in High-Risk Localisations of Cutaneous Squamous Cell Carcinoma: IMP3 in Metastatic cSCC.

Simple Summary: High IMP3 expression is correlated with poorer prognosis in many tumour entities. To date, there have been no data on IMP3 expression and clinical outcome in high-risk localisations (lip, ear) of squamous cell carcinoma of the skin. These are almost twice as likely to metastasise compared to other sites. In this study, the tumour marker IMP3 showed clear correlations with aggressiveness features (lymph node metastases, local recurrences, and progression-free survival). The identification of these more-aggressive tumours could influence therapy and diagnostics (radicality of neck dissection, follow-up intervals, staging). The analysis method presented here is efficient and could be easily incorporated into a clinical workflow and used for prospective testing. Background: High IMP3 expression is correlated with a worse outcome. Until now, there have been no data about IMP3 expression and clinical outcome for high-risk localisation of squamous cell carcinoma of the skin (cSCC). Methods: One-hundred twenty-two patients with cSCC of the lip and ear were included, and IMP3 expression in the tumours was immunohistochemically assessed in different evaluation approaches. Subsequently, subgroups were analysed in a matched pair approach and correlated with clinical pathologic parameters. In the following, different IMP3 analysis methods were tested for clinical suitability. Results: We found a significant correlation between IMP3 expression and risk for lymph node metastasis, local relapse, and progression-free survival. Conclusions: On basis of our data, we suggest a prognostic benefit cutoff value for high (>50%) and low (<50%) IMP3 expression. Thus, IMP3 expression has a high scientific potential for further studies and could potentially be used as a prognostic marker in diagnostic and therapeutic decision-making. [ABSTRACT FROM AUTHOR]